DMRA Damora Therapeutics (DMRA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001800315
C-suite buying · 1Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
81
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about DMRA
Insiders, 180 days
+$245.5K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$56.0K
1 notice
Damora Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Damora Therapeutics, Inc. insiders bought a net $245.5K of stock across 2 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.4% of the 512,500 shares held after it.
- No other insider bought within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director, President and CEO Jarrett Jennifer bought about $252.9K of DMRA on Sep 25, 2026, the largest insider purchase at the company on our record; 81 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 10.7% of the 2,289 shares held after it.
- No other insider sold within 30 days.
- 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Winslow Garrett sold about $7.3K of DMRA on Jul 6, 2026, the largest insider sale at the company on our record; 81 funds added in the latest 13F quarter.2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$245.5K over 180 days
+$252.9K over 90 days
more than 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
81 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.6% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
more than 62% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DMRA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+156.5%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DMRA: institutional holders (13F)
13F holdings, latest reported quarter
9,232,979 sh
$240.1M
8,713,000 sh
$226.6M
3,783,000 sh
$98.4M
3,603,595 sh
$93.7M
3,162,068 sh
$82.2M
Congress trades in DMRA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DMRA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Firmani Lori
Filed 2026-08-06
$56.0K
Firmani Lori
Filed 2026-06-22
$193.1K
DMRA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
JPMorgan Small Cap Growth Fund
$19.3M position · as of 2026-06-30
0.7%
JPMorgan Small Cap Blend Fund
$6.2M position · as of 2026-06-30
0.4%
VIP Health Care Portfolio
$3.1M position · as of 2026-06-30
0.3%
Select Health Care Portfolio
$12.4M position · as of 2026-05-31
0.2%
Select Biotechnology Portfolio
$11.3M position · as of 2026-05-31
0.2%
T. Rowe Price Health Care ETF
$46.5K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
$2.1M
$709.0K
+28%
n/a
2024
$1.4M
$1.2M
$759.7K
-74%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $245.5K bought by insiders over 180 days, 81 funds added last quarter, $56.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
DMRA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM DMRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM DMRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$44.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DMRA
| FY Dec 2025 | -$6.9M |
| FY Dec 2024 | -$18.8M |
| FY Dec 2023 | -$37.1M |
| FY Dec 2022 | -$43.1M |
| FY Dec 2021 | -$52.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity DMRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt DMRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-99.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity DMRA
| FY Dec 2025 | -163.8% |
| FY Dec 2024 | -89.0% |
| FY Dec 2023 | -81.5% |
| FY Dec 2022 | -68.9% |
| FY Dec 2021 | -36.6% |
| Jun 2026 | -99.7% |
| Mar 2026 | -89.5% |
| Dec 2025 | -163.8% |
| Sep 2025 | -109.5% |
| Jun 2025 | -96.1% |
| Mar 2025 | -88.3% |
| Dec 2024 | -89.0% |
| Sep 2024 | -72.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-94.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DMRA
| FY Dec 2025 | -151.1% |
| FY Dec 2024 | -77.5% |
| FY Dec 2023 | -68.8% |
| FY Dec 2022 | -63.1% |
| FY Dec 2021 | -35.2% |
| Jun 2026 | -94.3% |
| Mar 2026 | -85.4% |
| Dec 2025 | -151.1% |
| Sep 2025 | -92.9% |
| Jun 2025 | -81.0% |
| Mar 2025 | -77.3% |
| Dec 2024 | -77.5% |
| Sep 2024 | -57.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital DMRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-102.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DMRA
| FY Dec 2025 | -164.5% |
| FY Dec 2024 | -92.1% |
| FY Dec 2023 | -84.5% |
| FY Dec 2022 | -68.1% |
| FY Dec 2021 | -36.8% |
| Jun 2026 | -102.7% |
| Mar 2026 | -91.0% |
| Dec 2025 | -164.5% |
| Sep 2025 | -112.1% |
| Jun 2025 | -97.9% |
| Mar 2025 | -91.1% |
| Dec 2024 | -92.1% |
| Sep 2024 | -74.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
2.84x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing DMRA
| FY Dec 2025 | 5.78x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 3.47x |
| Mar 2026 | 4.91x |
| Dec 2025 | 5.78x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value DMRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield DMRA
| FY Dec 2025 | -22.7% |
| FY Dec 2024 | -307.3% |
| FY Dec 2023 | -7.6% |
| FY Dec 2022 | -5.9% |
| FY Dec 2021 | -2.7% |
| Jun 2026 | -2.8% |
| Mar 2026 | -1.6% |
| Dec 2025 | -22.7% |
| Sep 2025 | -252.1% |
| Jun 2025 | -298.5% |
| Mar 2025 | -373.8% |
| Dec 2024 | -307.3% |
| Sep 2024 | -7.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing DMRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$210.9M | -$22.3M | -$39.9M | -$61.2M |
| Net income | -$209.8M | -$21.4M | -$38.3M | -$61.6M |
| EPS (diluted) | 3.98 | -18.53 | -36.08 | -2.43 |
| Operating cash flow | -$6.7M | -$18.6M | -$36.9M | -$42.9M |
| Cash | $257.6M | $14.2M | $21.5M | $32.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
DMRA Stock Sonar score 4/7 axes
Find similar shapesCompareDMRA ranks highest on insider conviction (69th percentile) and institutional and government (60th), and lowest on profitability (28th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DMRA filings, in plain words
Are Damora Therapeutics insiders buying or selling DMRA?
In the 180 days to 2026-10-28, Damora Therapeutics insiders were net buyers, a net $245.5K: $252.9K of purchases and $7.3K of sales reported on Form 4, by 1 buyer and 1 seller.
Are there planned insider sales of DMRA?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $56.0K of stock; the latest, by Firmani Lori, was filed 2026-08-06.
Read the full summary
In the 180 days to 2026-10-28, Damora Therapeutics insiders were net buyers of DMRA, a net $245.5K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Purchases outweighed sales more than tenfold by value. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $56.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
